September 12th 2024
The GSK reformulation induced acceptable immune responses for both influenza A and B strains, overcoming a setback earlier in the ability to successfully neutralize the latter.
COVID-19 Vaccine Update: FDA Amends Pfizer, Moderna EUAs, Simplifying Use of Bivalent Formulations
April 18th 2023The FDA action ends the use of monovalent COVID-19 mRNA vaccines from Pfizer/BioNTech and Moderna in favor of bivalent formulations to simplify the vaccination schedule, said the Agency.